915720-21-7 Usage
General Description
AZ-23 is a chemical compound that belongs to the group of azole antifungal agents. AZ-23 is known for its broad-spectrum activity against a variety of fungal species, making it a valuable tool in the treatment of fungal infections. AZ-23 works by inhibiting the production of ergosterol, a key component of fungal cell membranes, leading to disruption of the fungal cell structure and eventually cell death. It has shown promising results in clinical studies and has the potential to be used in both human and veterinary medicine for the treatment of a wide range of fungal infections. Further research and development of AZ-23 are ongoing to explore its full therapeutic potential and to optimize its efficacy and safety profile.
Check Digit Verification of cas no
The CAS Registry Mumber 915720-21-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,5,7,2 and 0 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 915720-21:
(8*9)+(7*1)+(6*5)+(5*7)+(4*2)+(3*0)+(2*2)+(1*1)=157
157 % 10 = 7
So 915720-21-7 is a valid CAS Registry Number.
915720-21-7Relevant articles and documents
Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases
Wang, Tao,Lamb, Michelle L.,Scott, David A.,Wang, Haixia,Block, Michael H.,Lyne, Paul D.,Lee, John W.,Davies, Audrey M.,Zhang, Hai-Jun,Zhu, Yanyi,Gu, Fei,Han, Yongxin,Wang, Bin,Mohr, Peter J.,Kaus, Robert J.,Josey, John A.,Hoffmann, Ethan,Thress, Ken,MacIntyre, Terry,Wang, Haiyun,Omer, Charles A.,Yu, Dingwei
experimental part, p. 4672 - 4684 (2009/07/25)
The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4- aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of 10z (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.
